All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Srdan Verstovsek, MD Anderson Cancer Center, Houston, US. We asked, How effective are JAK inhibitor combinations for patients with myelofibrosis?
How effective are JAK inhibitor combinations for patients with myelofibrosis?
JAK inhibitors can control progressive symptomatic splenomegaly and disease-related symptoms; however, they may also worsen anemia in patients with myelofibrosis. Verstovsek outlines JAK inhibitor combinations of luspatercept, CPI-0610, navitoclax, and hypomethylating agents to help manage a wider range of symptoms.
How to switch therapies in patients with myelofibrosis
Myelofibrosis (MF) is a heterogeneous disease with limited treatment options, which may cause treatment challenges when patients no longer respond to one therapy. Donal P. McLornan and Claire N....
Editorial Theme | The management of relapsed/refractory myelofibrosis: Part 4 – investigational combination approaches
The unmet clinical need in treating patients with relapsed or refractory myelofibrosis (R/R MF) is well acknowledged by...
Subscribe to get the best content related to MPN delivered to your inbox